Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aframomum melegueta is a perennial herb in the ginger family (Zingiberaceae) native to West Africa, widely known as Grains of Paradise. Traditionally used as a spice and in folk and herbal medicine, it is recognized for its pungent seeds containing active compounds such as 6-paradol, 6-gingerol, shogaol, tetrahydroparadol, α-humulene, and β-caryophyllene[1][2][3][7]. Its **mechanisms of action** include anti-inflammatory (COX-2 inhibition, downregulation of inflammatory gene expression), thermogenic (increasing body heat and metabolism), antioxidant, membrane-stabilizing, and neuroactive effects (modulation of endocannabinoid, serotoninergic, and GABAergic systems, inhibition of FAAH)[1][4][6][7]. Traditionally, it has been used for gastrointestinal disorders, stimulating digestion, wound healing, fertility enhancement, pain relief, circulatory improvement, and as an anthelmintic, antiviral, and possibly anticancer and antidiabetic agent[1][2][7]. Human evidence supports its reduction in anxiety and improved sleep quality at moderate doses[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aframomum melegueta.